HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone ...

In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast ...

HER2-positive breast cancers have more HER2 receptors and can grow and spread faster than HER2-negative cancers. HER2 status should be tested regularly as it can change if the cancer recurs or spreads ...

"In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new ...

Dr. Beverly Moy is back on the ASCO Guidelines Podcast to discuss the latest guideline rapid recommendation update regarding sacituzumab govitecan for patients with hormone receptor-positive ...

The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...

An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available. Imagion Biosystems has announced positive results from its collaboration with Wayne State University on the MagSense® HER2 ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ASCO Annual Meeting. This abstract does not include a full text component.